Form 8-K Jade Biosciences, Inc. For: Jun 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Wall St advances as Microsoft results ease AI spending fears
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- KBR names its Mission Technology Solutions spinoff Trinzic
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Jade Biosciences licenses antibody program from Paragon Therapeutics
July 1, 2026 5:13 PM EDTJade Biosciences (NASDAQ: JBIO) entered into a license agreement with Paragon Therapeutics on June 29, 2026, securing worldwide exclusive rights to develop and commercialize certain monospecific antibodies targeting an undisclosed biological target across all human disease therapeutic areas.
Under the agreement, Jade Biosciences is obligated to pay Paragon up to $22.0 million in development and... More
